Brugada Syndrome

• Primary sodium channel dysfunction and loss-of-function mutations: The majority of cases (~80%) involve mutations in SCN5A, which encodes the alpha-1 subunit of the cardiac L-type sodium channel (Nav1.5). These mutations cause either reduced channel expression (trafficking defects), decreased channel opening probability (gating defects), or increased channel inactivation. The loss of rapidly inactivating sodium current in phase 1 of the ventricular action potential creates the substrate for reentrant arrhythmias. At the organ level, this produces unopposed outward current during the early repolarization phase in the right ventricular outflow tract (RVOT), where sodium channel expression is naturally lower and potassium channel expression (particularly Ito, the transient outward potassium current) is relatively higher. The result is a prominent "spike-and-dome" morphology in epicardial but not endocardial action potentials, creating transmural voltage gradients that enable circus movement reentry.

• Right ventricular outflow tract-specific vulnerability: The RVOT demonstrates exaggerated phase 1 repolarization due to a naturally lower sodium current density and higher Ito density compared to other regions. When sodium channel function is compromised by SCN5A mutations, the outward potassium current unopposed by sufficient inward sodium current drives premature repolarization. This creates a spatially heterogeneous action potential duration (APD), with the epicardium repolarizing before the endocardium. The resulting transmural voltage gradient facilitates reentrant circuits and creates the distinctive ECG appearance. This explains the clinical observation that arrhythmias characteristically originate in the RVOT region and why structural abnormalities are notably absent despite life-threatening arrhythmias.

• Temperature and autonomic modulation of arrhythmia vulnerability: Brugada syndrome exhibits profound fever sensitivity, with fever (<39°C) paradoxically unmasking or exacerbating the diagnostic ECG pattern and triggering arrhythmias in up to 80% of symptomatic patients. Elevated temperature increases inactivation of sodium channels and reduces sodium current amplitude, worsening the substrate. Conversely, cooling suppresses the ECG changes. Slow heart rates (during sleep, bradycardia-dependent episodes) and vagal tone also increase arrhythmia risk by prolonging the vulnerable window for reentry. These observations explain the characteristic nocturnal presentation of symptoms and the increased risk during febrile illness. Adrenergic stimulation paradoxically suppresses the ECG findings in some patients, potentially through increased calcium current offsetting reduced sodium current.

• Genetic heterogeneity and modifier effects: Beyond SCN5A, mutations in genes encoding calcium channel subunits (CACNA1C, CACNB2b), potassium channels (KCNE3, KCNH2), and scaffolding proteins modify the phenotype. Additionally, genetic modifiers and polygenic variation influence clinical expression, explaining variable penetrance and expressivity within families. The same SCN5A mutation may cause asymptomatic ECG changes in one family member and sudden death in another, highlighting the importance of gene-environment and gene-gene interactions. Polymorphisms in sodium channel modifying genes (such as those affecting channel trafficking) significantly influence arrhythmia risk independent of the primary pathogenic mutation.

• Genetic mutations in SCN5A and related genes (primary cause): Loss-of-function mutations in SCN5A account for approximately 20-30% of genotyped Brugada cases, with autosomal dominant inheritance and incomplete penetrance. More than 400 distinct mutations have been catalogued, including missense mutations, frameshift deletions, splice site mutations, and in-frame deletions. Mutations causing reduced channel trafficking to the cardiac membrane (e.g., due to impaired folding or trafficking domain defects) show particularly high disease penetrance. Non-SCN5A mutations in CACNA1C, CACNB2b, SCN1B (beta-1 regulatory subunit), KCNE3, KCNH2, and HEY2 account for the remaining genotyped cases. Males demonstrate higher clinical penetrance and more severe phenotypes than females, likely due to testosterone effects on sodium channel expression and function, representing a critical distinction for clinical prognostication.

• Male gender and hormonal factors: Males demonstrate 8-10 fold higher symptomatic presentation rates and account for >80% of patients with sudden cardiac death from Brugada syndrome. Testosterone enhances sodium channel inactivation (opposing the loss-of-function effect of mutations), effectively worsening the electrical substrate. Postpartum women occasionally develop Brugada manifestations due to hormonal changes, highlighting the protective role of estrogen. Oral contraceptive use may suppress symptom expression in heterozygous females. This gender differential is among the most striking clinical features and reflects underlying pharmacogenetic interactions.

• Fever and intercurrent illness: Febrile episodes unmask or exacerbate the diagnostic ECG pattern in up to 70-80% of symptomatic patients and represent a potent trigger for arrhythmias. Even minor febrile illnesses (respiratory infections, urinary tract infections) sufficiently elevate temperature to trigger events. The mechanism reflects temperature-dependent changes in sodium channel kinetics and the voltage dependence of channel inactivation. Patients should be counseled to aggressively treat fever and maintain normothermia.

• Drug-induced unmasking and arrhythmia triggers: A large number of medications can unmask the Brugada ECG pattern or increase arrhythmia risk, including class IA antiarrhythmic agents (flecainide, propafenone, quinidine—contraindicated), tricyclic antidepressants (amitriptyline, imipramine), typical antipsychotics (haloperidol, chlorpromazine), antihistamines (terfenadine, astemizole—withdrawn), antibiotics (trimethoprim, fluoroquinolones), anesthetics (propofol—used cautiously), and cocaine. The mechanism involves sodium channel blockade, either directly or indirectly. A comprehensive drug interaction database should be reviewed before prescribing any new medication in diagnosed patients.

• Bradycardia and autonomic factors: Slow heart rates, particularly during sleep and in the setting of high vagal tone, increase arrhythmia risk by lengthening the vulnerable window for reentry. Patients with baseline bradycardia or sleep-related heart rate depression show higher event rates. Conversely, sympathetic activation (exercise, stress) sometimes suppresses the ECG changes, explaining the predominantly nocturnal presentation of symptoms.

• Electrolyte abnormalities: Hypokalemia, hypomagnesemia, and hypocalcemia may precipitate or unmask arrhythmias, though these are less specific triggers than fever or drugs. Correction of electrolyte abnormalities should be part of comprehensive management.

• Palpitations and syncope: Patients often experience rapid palpitations immediately preceding loss of consciousness, representing polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF). Syncope typically occurs without warning during rest or sleep, occasionally with a prodrome of palpitations. Some patients experience recurrent syncope in clusters, suggesting triggering events. The syncope is notably not exertional, distinguishing it from hypertrophic cardiomyopathy or long QT syndrome, though exertion may occur as a stress trigger in some cases.

• Sudden cardiac death as presentation: Approximately 1-4% of Brugada patients per year experience sudden cardiac death if untreated and stratified to high-risk categories. Young males (typically aged 25-50 years) represent the predominant demographic. Death may be the first manifestation despite no preceding cardiac symptoms, underscoring the importance of screening family members after an index case. Nocturnal sudden unexplained death in otherwise healthy young adults is a classic presentation, particularly recognized in Southeast Asian populations where the syndrome is endemic (Sudden Unexplained Nocturnal Death Syndrome, SUNDS).

• Asymptomatic presentation with incidental ECG findings: Many patients are identified through screening after a family member's diagnosis or incidentally during routine ECG for unrelated reasons. The presence of diagnostic ECG changes alone does not predict symptomatic status, reflecting incomplete penetrance and variable expressivity. Approximately 50% of genotyped patients with pathogenic SCN5A mutations remain asymptomatic throughout life.

• Fever-triggered arrhythmias: Symptomatic patients frequently describe syncope episodes coinciding with fever, upper respiratory infections, or gastrointestinal illnesses. The temporal relationship between fever and arrhythmias is sufficiently characteristic that fever should raise suspicion for Brugada syndrome in young patients presenting with syncope. Some patients have documented multiple episodes specifically triggered by moderate fevers (38-39°C).

• Physical examination findings: The physical examination is typically completely normal, reflecting the absence of structural heart disease. The diagnosis cannot be suspected on clinical grounds alone; the ECG must be obtained. No murmurs, gallops, or other cardiac auscultatory findings are present. This absence of structural disease on imaging distinguishes Brugada syndrome from other causes of sudden cardiac death and has important prognostic implications for preserved ventricular function and normal life expectancy in the absence of arrhythmic events.

• Clinical variants and incomplete penetrance: A minority of patients demonstrate "arrhythmogenic right ventricular cardiomyopathy (ARVC)-like" phenotype with subtle structural changes, though frank ARVC is typically distinguished by more pronounced myocardial replacement and dysfunction. Brugada phenocopy describes patients with ECG appearances mimicking Brugada syndrome but caused by secondary conditions (atypical RVOT arrhythmias, early repolarization patterns). The distinction requires integration of clinical context, genetic testing, and functional studies.

• Characteristic electrocardiographic pattern (diagnostic criterion): The hallmark ECG finding comprises ST-segment elevation ≥2 mm in leads V1-V2 followed by a negative T wave, creating a distinctive "coved" or "saddleback" appearance depending on subtype. The ST elevation typically begins at the QRS-ST junction (J point) with rapid descent. Three Brugada ECG types are recognized: Type 1 (coved) with >2 mm ST elevation at the J point followed by negative T wave (most specific and diagnostic); Type 2 (saddle-back) with 1-2 mm ST elevation at J point followed by positive T wave; and Type 3 (saddle-back) with <1 mm elevation. Only Type 1 pattern is definitively diagnostic of Brugada syndrome; Types 2 and 3 require additional supportive evidence (positive genetic testing, family history, or induced VF on electrophysiologic study). The pattern may be dynamic and intermittent, necessitating serial ECGs or ECG monitoring to establish diagnosis. Fever unmasks the pattern in many patients, such that baseline resting ECGs may appear normal in asymptomatic carriers. Sensitivity of diagnostic Type 1 ECG is 50-80% in confirmed genetic cases due to intermittent pattern expression, whereas specificity approaches 95-99% for identifying disease-susceptible individuals.

• Electrophysiologic study for diagnosis and risk stratification: Programmed ventricular stimulation (PVS) using incremental pacing with up to triple extrastimuli induces polymorphic VT or VF in approximately 60-70% of symptomatic patients and 30% of asymptomatic carriers. Inducibility on PVS was historically used for risk stratification; however, inducibility alone has poor predictive value for identifying future spontaneous arrhythmia risk in asymptomatic patients, and PVS-guided therapy is no longer routinely recommended for initial risk assessment. PVS remains useful for diagnostic confirmation and for assessing response to drug therapy in specific clinical scenarios. Provocation maneuvers such as high-dose sodium channel blockers (ajmaline, flecainide, or procainamide IV) unmask the diagnostic Type 1 ECG pattern in up to 80% of suspected cases with non-diagnostic baseline ECGs, improving diagnostic sensitivity. The ajmaline challenge test (1 mg/kg IV over 10 minutes) is considered a gold standard for unmasking Type 1 pattern when baseline ECG is non-diagnostic but clinical suspicion is high.

• Genetic testing (SCN5A and related genes): DNA sequencing of SCN5A, CACNA1C, CACNB2b, SCN1B, and other implicated genes identifies pathogenic mutations in approximately 25-35% of probands with definite Brugada syndrome diagnosis based on Type 1 ECG. Positive genetic testing confirms heritable disease and enables cascade family screening to identify at-risk relatives. Variants of uncertain significance (VUS) are frequent and require functional studies or large family segregation data for interpretation. Genetic testing is recommended for all patients with diagnostic Type 1 ECG pattern and should be considered for those with Type 2-3 patterns in appropriate clinical context. The presence of a pathogenic SCN5A mutation in a symptomatic patient strengthens the diagnosis and mandates cascade screening, though mutation negativity does not exclude Brugada syndrome (genetic heterogeneity and non-genetic mimics).

• Risk stratification criteria for ICD implantation: Multiple risk stratification approaches exist, reflecting evolving understanding of who requires ICD therapy. Established risk factors for spontaneous arrhythmias include: (1) prior aborted sudden cardiac death or sustained VF; (2) symptoms (syncope) attributable to Brugada syndrome; (3) fever-induced symptoms; (4) male gender; (5) younger age at diagnosis; (6) early repolarization on ECG; (7) positive family history of sudden cardiac death; (8) inducible VF on PVS; and (9) homozygous or compound heterozygous SCN5A mutations. The 2019 ESC Guidelines recommend ICD implantation for: (a) all symptomatic patients (recurrent syncope, survived cardiac arrest); (b) asymptomatic patients with high-risk features including young age, male gender, earliest ECG pattern (Type 1), short QT interval, and/or inducible VF on PVS (remaining controversial). Risk scores such as the Brugada Risk Calculator (incorporating age, gender, symptoms, fever sensitivity, ECG type, and QT interval) help quantify individual risk; however, no universally accepted risk stratification algorithm exists**, and decisions are individualized based on shared decision-making, regional practice patterns, and patient preferences. Studies demonstrate that ICD implantation prevents >95% of deaths in high-risk patients, supporting aggressive intervention in symptomatic and selected asymptomatic populations.

• Imaging studies (echocardiography, cardiac MRI, coronary angiography): Transthoracic echocardiography is normal by definition, demonstrating preserved left ventricular function, normal chamber dimensions, and no structural abnormalities. Echocardiography is obtained to exclude structural mimics (ARVC, dilated cardiomyopathy, hypertrophic cardiomyopathy). Cardiac MRI may show subtle structural changes in the RVOT in rare cases but is not required for diagnosis. Coronary angiography is reserved for symptomatic older patients or those with atypical presentations to exclude acute coronary syndrome. CT coronary angiography can be considered for non-invasive coronary assessment in intermediate-risk patients.

• Differential diagnosis considerations: Important mimics include (1) ARVC, distinguished by prominent structural remodeling, depolarization abnormalities (epsilon waves), and evidence of myocardial scar or fatty infiltration; (2) Early repolarization syndrome, characterized by J waves or ST elevation in multiple leads (not limited to V1-V2) and benign prognosis in most cases; (3) Type 2 or 3 pattern mimics (RVOT cardiomyop

Immediate stabilization (arrhythmic emergency)

• Defibrillation: ventricular fibrillation / pulseless VT is treated with immediate unsynchronized defibrillation and standard ACLS. Reversible aggravators must be corrected simultaneously — aggressive antipyresis with acetaminophen, repletion of potassium and magnesium, and withdrawal of any sodium-channel–blocking drug or cocaine.
• Isoproterenol infusion: the drug of choice for electrical storm (recurrent VF/multiple ICD shocks). Beta-adrenergic stimulation augments L-type calcium current, restoring the epicardial action potential dome and collapsing the transmural repolarization gradient — the ECG pattern normalizes as the arrhythmia stops. Endorsed by the HRS/EHRA/APHRS expert consensus on inherited primary arrhythmia syndromes.

Definitive therapy

• Implantable cardioverter-defibrillator (ICD): the only intervention shown to prevent sudden death. Per the 2017 AHA/ACC/HRS ventricular arrhythmia/SCD guideline, an ICD is recommended for survivors of cardiac arrest, documented sustained ventricular arrhythmia, and is reasonable in patients with spontaneous type 1 pattern plus arrhythmic syncope. ICDs are not indicated for asymptomatic patients whose type 1 pattern appears only after drug provocation — these patients receive counseling, fever management, and drug avoidance.

Pharmacologic adjuncts

• Quinidine: reduces the transient outward potassium current (Ito), the very current that drives premature epicardial repolarization in the RVOT. Used for recurrent arrhythmias, frequent ICD shocks, or when an ICD is refused or unavailable. Note the paradox: despite being a sodium-channel blocker, its dominant Ito blockade is therapeutic.
• Ineffective agents: beta blockers and amiodarone do not prevent sudden death here and should not substitute for an ICD.

Refractory disease

• Epicardial catheter ablation of the RVOT arrhythmogenic substrate for recurrent storm or repeated appropriate shocks despite quinidine.

Contraindicated

• Class IC and IA sodium-channel blockers used therapeutically (flecainide, propafenone, procainamide), tricyclic antidepressants, certain antipsychotics, and cocaine — all accentuate the substrate. Patients should be directed to a curated avoid-drug list before any new prescription or anesthetic.

Disease-related

• Polymorphic VT degenerating to ventricular fibrillation (emergency): phase 2 reentry across the RVOT transmural voltage gradient. Signalled by nocturnal syncope, agonal respirations, or witnessed arrest; ICD interrogation shows fast polymorphic VT/VF rather than monomorphic VT.
• Electrical storm (emergency): multiple discrete VF episodes within 24 hours, classically during febrile illness. Recognized by clustered ICD shocks; the ECG typically shows marked accentuation of the coved ST elevation, which regresses with isoproterenol and cooling.
• Fever-precipitated arrhythmia (emergency in children): temperature-dependent sodium-channel inactivation. In pediatric carriers, a febrile illness with syncope or a "seizure" may in fact be self-terminating VF — obtain an ECG during fever.
• Atrial fibrillation and other atrial arrhythmias: the same SCN5A loss of function affects atrial myocardium; presents as palpitations, and in ICD patients as inappropriate shocks from rapid AF conducted above the detection rate.
• Sinus node dysfunction and conduction delay (overlap syndrome): reduced peak sodium current slows conduction; look for PR prolongation, QRS widening, or sinus bradycardia/pauses — bradycardia itself further favors reentry.

Treatment-related

• Inappropriate ICD shocks: disproportionately common because patients are young, active, and often have T-wave oversensing or sinus/atrial tachycardia. Signalled by shocks without preceding syncope; managed by reprogramming, not device removal.
• Lead failure, pocket hematoma, and device infection (emergency): fever with pocket erythema or Staphylococcus bacteremia mandates evaluation for lead-associated endocarditis and complete system extraction.
• Quinidine toxicity: GI intolerance (diarrhea is the leading cause of discontinuation), thrombocytopenia, cinchonism, and QT prolongation with torsades de pointes (emergency) — monitor the QT after initiation.
• Isoproterenol effects: sinus tachycardia, hypotension, and demand ischemia in older patients.
• Epicardial ablation: pericardial bleeding and cardiac tamponade (emergency) — hypotension with elevated JVP and pulsus paradoxus.
• Psychological morbidity: shock-related anxiety, PTSD, and device-avoidance behavior in adolescents.

• The stem picture: a previously healthy young man, often Southeast Asian, with syncope or arrest during sleep or at rest, a structurally normal heart, and coved ST elevation with an inverted T wave in V1–V2 (pseudo-right bundle branch block). Only the type 1 (coved) pattern is diagnostic.
• Single best next step when the ECG is equivocal: check for and treat fever, repeat the ECG (including high right precordial lead placement), and if suspicion persists, perform a sodium-channel blocker provocation test (ajmaline or procainamide) — the same drug class that is therapeutically forbidden is used diagnostically.
• The association examiners love: SCN5A — loss of function causes Brugada syndrome, whereas gain of function (impaired inactivation, persistent late sodium current) in the same gene causes LQT3. Both cause nocturnal/rest-related events; the QT interval separates them.
• Only ICD prevents death. A stem offering a beta blocker or amiodarone for a Brugada arrest survivor is the classic distractor — neither works. Quinidine (an Ito blocker) is the adjunct for recurrent shocks or storm; isoproterenol is the answer for electrical storm.
• Do not implant an ICD in an asymptomatic patient whose type 1 pattern appeared only on drug challenge — per the 2017 AHA/ACC/HRS guideline, management is drug avoidance, aggressive antipyretics, and family cascade screening.
• Fever is the tested trigger: acetaminophen plus an ECG during any febrile illness; in a child, a febrile "seizure" with collapse may be self-terminating VF.
• Differentiate the mimics: ARVC has structural RV disease, epsilon waves, and inverted T waves extending beyond V2; early repolarization syndrome shows J waves in inferolateral leads; hypertrophic cardiomyopathy and catecholaminergic polymorphic VT cause exertional syncope, not rest/sleep events.
• Inheritance: autosomal dominant with incomplete penetrance and strong male predominance — screen first-degree relatives with an ECG regardless of symptoms.